Lille Neuroscience & Cognition, Alzheimer & Tauopathies
We are interested in the effects of caffeine in the brain and neurodegeneration using molecular to genetic, epidemiological and clinical approaches. We are particularly interested on one caffeine target, the widely expressed adenosine A2A receptors, with the goal to uncover how this caffeine target is prone to impact synapses, glial cells and memory in neurodegeneration by combining transgenic conditionnal approaches, 3D morphology, omics, biochemistry and neuropathology.
Technical skills: Transgenic models, viral models, DREEAD, Behavior, 3D imaging in vivo, biochemistry, neuropathology, sequencing
References:
Paiva I, Cellai L, Meriaux C, Poncelet L, Nebie O, Saliou JM, Lacoste AS, Papegaey A, Drobecq H, Le Gras S, Schneider M, Malik EM, Müller CE, Faivre E, Carvalho K, Gomez-Murcia V, Vieau D, Thiroux B, Eddarkaoui S, Lebouvier T, Schueller E, Tzeplaeff L, Grgurina I, Seguin J, Stauber J, Lopes LV, Buée L, Buée-Scherrer V, Cunha RA, Ait-Belkacem R, Sergeant N, Annicotte JS, Boutillier AL, Blum D (2022) Caffeine intake exerts dual genome-wide effects on hippocampal metabolism and learning-dependent transcription. The Journal of Clinical Investigation 132(12):e149371.
Dewaeles E, Carvalho K, Fellah S, Sim J, Boukrout N, Caillierez R, Ramakrishnan H, Van der Hauwaert C, Vijaya Shankara J, Martin N, Massri N, Launay A, Folger JK, de Schutter C, Larrue R, Loison I, Goujon M, Jung M, Le Gras S, Gomez-Murcia V, Faivre E, Lemaire J, Garat A, Beauval N, Maboudou P, Gnemmi V, Gibier JB, Buée L, Abbadie C, Glowacki F, Pottier N, Perrais M, Cunha RA, Annicotte JS, Laumet G, Blum D*, Cauffiez C*. Istradefylline protects from cisplatin-induced nephrotoxicity and peripheral neuropathy while preserving cisplatin antitumor effects. J Clin Invest. 2022 Nov 15;132(22):e152924. doi: 10.1172/JCI152924.
Chang CP, Chang YG, Chuang PY, Nguyen TNA, Wu KC, Chou FY, Cheng SJ, Chen HM, Jin LW, Carvalho K, Huin V, Buée L, Liao YF, Lin CJ, Blum D* & Chern Y* (2021) Equilibrative nucleoside transporter 1 inhibition rescues energy dysfunction and pathology in a model of tauopathy. Acta Neuropathol Com 9(1):112.
Carvalho K, Faivre E, Pietrowski MJ, Marques X, Gomez-Murcia V, Deleau A, Huin V, Hansen JN, Kozlov S, Danis C, Temido-Ferreira M, Coelho JE, Mériaux C, Eddarkaoui S, Le Gras S, Dumoulin M, Cellai L, NeuroCEB Brain Bank, Landrieu I, Chern Y, Hamdane M, Buée L, Boutillier AL, Levi S, Halle A, Lopes LV & Blum D (2019) Exacerbation of C1q dysregulation, synaptic loss and memory deficits in Tau pathology linked to neuronal adenosine A2A receptors. Brain 142(11):3636-3654. DB corresponding author 15.255
Laurent C*, Burnouf S*, Ferry B, Batalha V, Coehlo J, Baqi Y, Malik E, Marciniak E, Parrot S, Van der Jeugd A, Faivre E, Flaten V, Ledent C, d’Hooge R, Sergeant N, Hamdane M, Humez S, Müller CE, Lopes LV, Buée L & Blum D (2016) A2A adenosine receptor deletion is protective in a mouse model of Tauopathy. Molecular Psychiatry 21(1):97-107. doi: 10.1038/mp.2015.115.
Travaillons ensemble
Contactez-nous pour que nous puissions travailler ensemble.
